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What's in a Name?
Henry Dale and Adrenaline, 1906
E M TANSEY*
By the beginning of the twentieth century the use of widespread advertising, trade
names, and specialized marketing techniques was a distinctive feature ofthe commercial
world. These attributes were well developed in the trade in medicines, a field that ranged
from quack cures and secret remedies through proprietary brands to "ethical pharmacy".1
The British pharmaceutical firm, Burroughs, Wellcome & Co. had, by that time, achieved
considerable success in promoting itself as an ethical company guided by scientific
principles and remote from the quackery and chicanery of pill peddlers and nostrum-
mongers. A component of that ethical behaviour was the maintenance of their own
production and advertising standards and the proper recognition of others' commercial
rights.
In the final decade of the nineteenth century Burroughs, Wellcome & Co. had
established quasi-independent laboratories, the Wellcome Physiological Research
Laboratories (WPRL), in which physiologists and pharmacologists were employed to
undertake basic research not directly or necessarily associated with the company's
commercial enterprises. One such scientist was the future Nobel Laureate Henry Dale,
who in 1906 wished to publish a paper in which the word "adrenaline" appeared.2 This
was then the commonly accepted term, within Britain's physiological community, for the
active principle of the suprarenal gland. However, the word "Adrenalin" was a registered
trademark of the American pharmaceutical firm Parke, Davis & Co., and Dale's intended
use was forbidden by Henry Wellcome. Dale and his colleagues refused to accept this
injunction, and the ensuing debates raised important issues within the Wellcome
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organization, and beyond.3 These included technical questions of chemical and
physiological nomenclature, and legal concerns about trademarks and trade names. They
also brought into sharp focus the then novel relationship between research laboratories
and commercial companies, and raised serious questions about scientific authority within
several laboratories that were part of the Burroughs, Wellcome empire. The episode also
illustrates difficulties thatfaced scientific workers associated with commercial enterprises,
in addition to providing an insight into the personal and scientific motivation and
development ofDale's distinguished career.
This paper focuses on just six weeks during 1906, following the transmission to the
Company headquarters of Dale's request to use the word adrenaline, during which office
and scientific staff employed by Wellcome, and outside advisers and official bodies, all
became embroiled in the affair.
The correspondence on this matter is scattered throughout the Archives of the
Wellcome Foundation and the Wellcome Institute, and also in the private papers of some
ofthe participants. The principal correspondents were Henry Wellcome, who was abroad
for most of the period; Henry Dale of the WPRL, and his director Walter Dowson; and
staff from their sister organization, the Wellcome Chemical Research Laboratories
(WCRL), most notably Dr Hooper Jowett. Much of the correspondence was channelled
through George Pearson, the Managing Director ofthe Company, and clerical staff at the
Company's offices usually prepared additional copies, which were then circulated to all
other interested parties. This complicates matters, since much ofthe communication took
place obliquely, as illustrated in a letter written by Henry Dale which begins: "Dear Mr.
Wellcome, Dr. Dowson has handed me a copy ofyour recent letter to Mr. Pearson . . .".4
More than forty letters and memoranda were written during this period, and several copies
of the same letters have been found in different locations, each annotated by their
respective recipient. It is from all these papers and their annotations that the following
account has been constructed.
The Welicome Physiological and Chemical
Research Laboratories
The original laboratory, which became the Wellcome Physiological Research
Laboratories, was established in 1894 to produce the new "biological" therapeutics, the
serum anti-toxins.5 This initiative was very much the brainchild ofHenry Wellcome, who
3 The word "Adrenalin" with and without the 5 Some ofthe other influences on the
initial capital and the final "e" was used almost development ofthe British pharmaceutical industry,
interchangeably in the publications and private in particular its relationship with the dye industry, are
correspondence cited in this paper. There does not explored in L F Haber, The chemical industry during
appear to have been a sharp distinction between the the nineteenth century: a study ofthe economic
usages, and although the former was used more often aspect ofapplied chemistry in Europe andAmerica,
to refer to the Parke, Davis product, its use was not Oxford, Clarendon Press, 1958, especially 'Chemical
consistent. manufacturers and their problems', pp. 186-230; and
4 Dale to Wellcome, 22 Feb. 1906. Henry R Stolz and R Schwaiberger, 'The correlation
Wellcome Archives in the Wellcome Institute for the between dye chemistry and pharmacy in creating the
History ofMedicine Library, henceforward modem chemotherapy', Hist. Tech., 1987,
WIHM:HSW. 3:193-203. E M Tansey, 'The Wellcome
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played a close personal part in their creation, promotion and subsequent activities.
Wellcome, a trained pharmacist from America, had, with Silas Mainville Burroughs,
founded a pharmaceutical company in Britain, which rapidly established a reputation for
scientific thoroughness and accuracy, largely owing to its range of pharmaceutical
preparations marketed underthetrade name of"Tabloid", an elision oftabletand alkaloid.
These precisely tableted, formulated and standardized compounds were enormously
successful. They were vigorously, even aggressively, marketed by the Company, and the
trade name was rigorously protected, often by recourse tothe law.6TheTabloid range was
a substantial part of the "scientific" image that the Company eagerly and successfully
projected. Its advertising material stressed the scientific orientation ofthe firm and, from
the very beginning of the company's existence, publicized the existence of laboratories
and specialized departments within the factories. These were almost certainly associated
with manufacturing processes in some way, ratherthan with innovativeresearch activities,
although it is worth remembering the caution,
that what one man may describe as a 'research laboratory' another may, with apparently equal
authority, call a development department. Who is to say, when we are dealing with organisations of
eighty or more years ago, which description is correct?7
The comment is particularly relevant to the Wellcome organization, as several,
variously designated laboratories were createdthroughout the 1890s andtheearly decades
ofthe twentieth century. Many ofthem were situated within the firm's factories, but two,
the WPRL and WCRL, were explicitly encouraged to undertake research work, and, the
Company maintained, they were independent ofcommercial activities and run on strictly
scientific lines.8 Despite that assertion, the raison d'e'tre of the Wellcome Physiological
Research Laboratories had been the production, standardization and packaging of anti-
toxin therapies, which were subsequently marketed by the parent pharmaceutical
company. The links between the WPRL and Burroughs, Wellcome & Co. were therefore
close, although those between the Company and the WCRL were even more intimate.
The Wellcome Chemical Research Laboratories were founded a year after the
Physiological Laboratories, in February 1895, when, in the midst of proceedings to
dissolve their partnership, Silas Burroughs died and Henry Wellcome became sole owner
of the company. Eight days after his partner's death, Wellcome wrote to a former
American college contemporary of his, Dr Frederick Power,9 inviting him to London,
promising,
Physiological Research Laboratories 1894-1904: the 7 D S L Cardwell, The organisation ofscience in
Home Office, pharmaceutical firms and animal England, London, Heinemann, 1972, pp. 175-6.
experiments', Med. Hist., 1989, 33:1-41, emphasizes 8 The independence ofthe labs seems highly
the specific situation ofthe Wellcome organization. questionable: they were funded as integral
6 Wellcome had several legal battles to reinforce components ofthe Burroughs, Wellcome Company;
his trademarks, especially "Tabloid", see G their staff were recorded as company employees; and
Macdonald, Inpursuit ofexcellence, London, they were administered by staff from the Company
Wellcome Foundation, 1980, p. 12; H Turner, Henry headquarters. For further details see Tansey, op. cit.,
Wellcome: the man, his collection and his legacy, note 5 above, pp. 35-6.
London, The Wellcome Trust and Heinemann, 1980, 9 For biographical details see J Parascandola,
pp. 14-15; R Rhodes James, Henry Wellcome, 'Frederick Belding Power', Dictionary ofscientific
London, Hodder & Stoughton, 1994, pp. 112-13, biography, 14 vols, New York, Charles Scribner's
292-3. Sons, 1970-80, vol. 11, pp. 120-1.
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to fit up for you a most thorough and complete experimental laboratory near my offices,... I want
you for constant consultation as I propose to enter much more into scientific medical chemical
products.... I should not ask you to take up any business cares or actual manufacturing drudgery
but only experimental and strictly scientific work etc such as I know is most congenial to you.'0
Power accepted this attractive offer, and in July 1895 the opening of the "Wellcome
Research Laboratories" was celebrated in London with a resounding declaration from
Wellcome that they were quite distinct from his business. Although he hoped that they
might contribute something of value to him and to the wider world, "[T]he work", he
announced, "is to be carried out on no selfish lines ... controlled and dictated with the
highest regard for science."11
The Chemical Laboratories had a particularly close relationship with Wellcome and the
Company: the Director, Power, was a distinguished chemist and an old and valued friend
ofWellcome; the WCRL were physically situated next door to the Company headquarters
in the City of London; and their research was traditional analytical chemistry, the
experimental isolation, identification and, ultimately, the synthesis of new
chemotherapeutic compounds, the kind of work that Wellcome himself understood well.
In contrast, the scientific staff appointed to the WPRL were not distinguished figures in
medical research; the laboratories, originally in central London, were relocated in 1899 to
South London, some distance from the Company headquarters in the City; and the nature
of their work was essentially innovative, and moved ever further away from Wellcome's
own direct experience.12 In 1901 Wellcome endeavoured to expand the experimental
possibilities at the WPRL by applying for them to be registered with the Home Office,
under the terms ofthe 1876 Cruelty to Animals Act, as a place where animal experiments
could be performed. After a lengthy, and at times acrimonious, debate with the Home
Office, Wellcome finally obtained permission in 1901 for the WPRL to be registered.13
This opened up exciting new possibilities fororiginal research inexperimental physiology
andpharmacology,'4 and in 1904Wellcome sought advice fromErnest Starling, Professor
of Physiology at University College London, about a suitable person to work in his labs:
You will, I am sure, understand my anxiety-in view of the prospective importance ofthe work of
this Institution-to secure the services ofa man who is capable ofbroad and deep thinking, who has
fertility of mind, originality and alertness, and patient persistence; a man who will concentrate his
whole mind and energies on this work. I want the work in these laboratories to be done on the
highest scientific lines and with such thoroughness and precision that it will stand the test of time
and the keenest criticism.15
10 Wellcome to Power, 14 Feb. 1895, The 13 Tansey, op. cit., note 5 above, passim.
Wellcome Foundation Ltd Group Archives 14 Until that time the WPRL had been principally
(henceforward TWFL), Acc 82/1:box 12. engaged in routine anti-toxin production and
1 'Dinner to Dr Power: new research laboratory in bacteriological diagnosis, as detailed in Tansey, op.
London', Pharmaceut. J., 1896, 3:78-9. cit., note 5 above, pp. 3-5.
12 E M Tansey and R C E Milligan, 'The early 15 Wellcome to Starling, 2 June 1904, TWFL:LB7
history of the Wellcome Research Laboratories, Letter Book personal, 1903-1904, p. 399. Starling
1894-1914', in J Liebenau, G J Higby and E Stroud was a little uneasy about the relationship of the
(eds), Pillpeddlers: essays on the history ofthe WPRL to the commercial company, although he did
pharmaceutical industry, Madison, WI, The recommend Henry Dale.
American Institute for the History ofPharmacy,
1990, pp. 91-106.
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On Starling's advice, Wellcome offered ayoung Cambridge trained physiologist, Henry
Dale, the position of staff pharmacologist at the WPRL. Despite the poor possibilities of
obtaining a permanent position in the academic world atthat time, Dale was warned about
association with a commercial manufacturer by Cambridge friends, who counselled him
against "selling my scientific birthright for a mess of commercial pottage".16 Dale,
however, needed a job as he wished to marry, he wanted to stand on his own feet
scientifically, and the WPRL offered superb facilities for research, unhampered by
teaching. He accepted Wellcome's offer, and never regretted the decision.17
Thus, by the beginning of the twentieth century, Henry Wellcome had established two
ostensibly private laboratories, one in physiology, one in chemistry, with designated
Directors and employing growing numbers of scientifically trained staff. Both labs were
lavishly equipped with gas, electricity, water, telephones and the most modem fittings and
sophisticated equipment then available, and there were few routine, and no teaching,
obligations for their staffs. But, as suggested by Dale's diffidence when offered
employment, there were problems attracting suitable people to work in laboratories
connected, however remotely, with commercial interests. It should be emphasized here
that Henry Wellcome's initiatives in this direction were unique in Britain: no other
pharmaceutical manufacturer had developed scientific research programmes, and explicit
associations between trade and academe were virtually non-existent.18 The problem of
recruitment was especially acute in the WPRL as those with appropriate scientific
expertise in physiology, pharmacology and bacteriology were medically qualified, and
connection, however indirect, with a commercial company was not encouraged by the
medical authorities.19 Additionally, within the Wellcome organization, the scientific staff
from the research laboratories were regarded as ordinary company employees. Their
contracts stipulated precise working hours; a paltry annual leave with no allowance for
attendance at scientific meetings during working hours; and a requirement, when
necessary, to test and validate company products. Ripples of dissatisfaction regularly
surface in the company records as the management tried to deal with new staff and new
situations which did not easily conform to their working regulations. The contractual
obligations regarding communication and publication are of particular relevance to the
debate about the word adrenaline:
It is understood that you are to treat as strictly confidential, and respect as my property, all my
manufacturing processes, formulae, apparatus etc. and all improvements therein, and also any
inventions ornew discoveries which may be made by you or anyone else in my employment; on the
understanding that I shall not extract from you with respect to any discovery a confidence which is
contrary to the ethics of your profession. It is also understood that before publishing any
communications upon physiological matters or upon any work connected with the laboratories you
16 H H Dale, 'Autobiographical sketch', Perspec. Tansey (compilers), Pills andprofits: the selling of
Biol. Med., 1958, 1:125-37, quote on p. 129; E M medicine since 1870, an exhibition catalogue,
Tansey, 'Funding medical research before the London, The Wellcome Trust, 1994, pp. 4-16.
creation of the Medical Research Council', J. R. Soc. 19 Some ofthe prejudices of the Royal Colleges of
Med., 1994, 87:546-8. Physicians, and of Surgeons were expressly
17 Dale, ibid. articulated during Wellcome's campaign to get the
18 See E M Tansey, 'The founding of the Wellcome WPRL registered for animal experimentation, see
Physiological Research Laboratories: conflict or Tansey, op. cit., note 5 above, pp. 23-6.
concord in medical research', in K Arnold and E M
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are first to submit same to and obtain the approval ofthe Director. The two clausesjust written refer
to work done at any time either in or out ofthe Laboratories.20
These internal regulations were reinforced by external restrictions in publishing work
from the Wellcome laboratories. Some "controversy with respect to the publication of
papers" arose with the Pharmaceutical Journal, as the Pharmaceutical Society regarded
scientific papers from Wellcome staff as advertisements for the company; and whilst the
British Medical Journal agreed to publish Wellcome papers, they refused to provide
reprints that could be used for publicity.21
Adrenalin or Epinephrine?
Thus, in accordance with his contract, when Dale prepared a paper for publication in
1906 he passed the manuscript to his Director, Walter Dowson, for approval.22 The paper,
on the physiological and pharmacological effects of ergot of rye included experiments
using adrenaline, and it came to Wellcome's attention. He objected to the use ofthe word
adrenaline because Adrenalin was a registered trade-name of Parke, Davis & Co.23
Wellcome suggested instead that the word epinephrine should be used, as that was how
the WCRL denoted what he believed was the same chemical substance. Dale maintained
that within the British physiological community adrenaline was used to describe the
physiologically active principle of the adrenal glands, and did not imply a specific
commercial preparation. He considered epinephrine to be inappropriate and inaccurate,
and refused to use it instead of adrenaline.
So, in addition to the commercial and legal problems, there were apparently significant,
technical disagreements between the chemists and physiologists about the nature of the
extract of the suprarenal gland. Why was this a contentious issue? The physiological
effects of a gland extract were first reported in 1894, when a north-country medical
practitioner, George Oliver, visited the Professor of Physiology at University College
London, Edward Schafer.24 Oliver's personal experiments with an extract of the
suprarenal glands ofvarious animals had revealed an effect on blood pressure and arterial
diameter. The two men collaborated on a series of animal experiments in which they
20 Wellcome to John Mellanby, 1 Jan. 1902,
TWFL:LB17, Letter Book 1901-Feb. 1902, p.441.
21 Wellcome to Dowson, 31 Oct. 1904,
TWFL:LB8, Correspondence Personal 6 (1904-5), p.
188; 11 May 1905, ibid., p.488; British
Pharmaceutical Conference, Minutes of Executive
Committee, 1887-1911: 24 June 1904, pp. 268-9, 8
Aug. 1904, p. 270; 8 July 1907, p. 318. For the
British Medical Journal see, Wellcome to members
of the BMA Council, 21 Nov. 1900, TWFL:LB14
Letter Books 1900-1901, pp. 468, 468a; Fauke to
Jowett, 1 Nov. 1900, ibid., p. 470; Fauke to Power, 3
Nov. 1900, ibid., p. 471.
22 Dowson to Wellcome, 2 Feb. 1906; Wellcome's
comments, 5 Feb. 1906; both in TWFL: Acc
82/1:Box 23 'WPRL 1895-1922'.
23 The use ofdistinguishing trade names and
branded goods had developed especially during the
latter part ofthe nineteenth century, as commercial
markets and press and poster advertising expanded,
see, e.g., T Richards, The commodity culture of
Victorian England: advertising andspectacle
1851-1914, Stanford University Press, 1990, passim.
24 Accounts of the early experiments done on
extracts of suprarenal glands by Henry Dale are
based on the tradition that Oliver first recorded a
vasopressor effect by injecting extract into his young
son, see H H Dale, 'Natural chemical stimulators',
Edin. med. J., 1938, 45:461-80; idem, 'Accident and
opportunism in medical research', Br med. J., 1948,
ii:451-5. The legitimacy of the account is questioned
by H Barcroft and J F Talbot, 'Oliver and Schafer's
discovery ofthe cardiovascular action ofthe
suprarenal extract', Postgrad. med. J., 1968, 44:6-8,
who provide an useful exposition ofthe early
experimental work.
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demonstrated the effects of the extract when injected into anaesthetized animals.
Particularly marked was the constrictor (pressor) effect on the arterial system, which
resulted in raised blood pressure. Within a year they gave two presentations to the
Physiological Society, and publication ofthe discovery and its therapeutic possibilities in
haemostasis and in adrenal deficiency (Addison's disease) stimulated the search for a pure
extract ofthe active principle.25
An initial priority was to identify the chemical composition ofthe active principle, and
as early as 1895 two of Schafer's colleagues began chemical analyses of the material,
continuing, like all workers in the field, to use the cumbersome phrase "physiologically
active extract ofthe suprarenal glands".26 Others too were searching for the principle: the
German chemist Fraenkel suggested that it was a substituted catechol, probably a benzoyl
derivative, which he called spygmogenin, and Abel and Crawford of Johns Hopkins
University succeeded in isolating benzoate and sulphate derivatives from the gland.27 In
1899 Abel28 published a majorpaper announcing an extract which he named "epinephrin"
and von Furth isolated a similar compound, which he called "suprarenin".29
Physiologically, however, neither of these two chemicals had the same activity as the
crude extracts ofthe suprarenal gland.30 In 1900 the industrial chemist Jokichi Takamine
realized, after visiting Abel's lab, how to overcome the existing contamination problems,
and rapidly developed a further purification stage. He patented the techniques, and
arranged for Parke, Davis & Co. to market the pure crystalline substance as "Adrenalin",
25 G Oliver and E A Schafer, 'On the physiological
action ofextract ofthe suprarenal capsules', J.
Physiol., 1894, 16: i-iv; idem, 'On the physiological
action ofextract ofthe suprarenal capsules', ibid.,
1895, 17: ix-xiv; a full paper published later in the
year contained work from both earlier
communications plus new results, idem, 'The
physiological effects ofextracts ofthe suprarenal
capsules', ibid., 1895, 18:230-76. Oliver was one of
the first to suggest that an adrenal gland extract
could be used to treat Addison's disease, see G
Oliver, 'On the therapeutic employment ofthe
suprarenal glands', Br. med. J., 1895, ii:653-5. A
copy in the Wellcome Institute Library, originally
belonging to Burroughs, Wellcome & Co. is marked
in the margin, probably by Henry Wellcome.
26 B Moore, 'On the chemical nature of a
physiologically active substance occurring in the
suprarenal gland', J. Physiol., 1895, 17: xiv-xvii,
thought that the active principle was a pyridine
derivative; D N Nabarro, 'The proteids of suprarenal
capsules', ibid., pp. xvii-xviii.
27 S Fraenkel, 'Physiological action ofsupra-renal
capsules', J. Chem. Soc. Abstracts, 1897, 72:63-4,
from Wien. med. Blatter, 1896, 14; J J Abel and A C
Crawford, 'On the blood-pressure-raising constituent
of the suprarenal capsule', Johns Hopkins Hosp.
Bull., 1897, 8:151-7.
28 H H Dale, 'John Jacob Abel 1857-1938',
Obituary notices ofFellows ofthe Royal Society,
London, Royal Society, 1939, vol. 2, pp. 577-85;
Abel's contributions to American pharmacology are
covered by H H Swain, E M K Geiling and A
Heingartner, 'John Jacob Abel at Michigan: the
introduction ofpharmacology into the medical
curriculum', Univ. Michigan med. Bull., 1963,
29:1-14; J Parascandola, 'John J Abel and the early
development ofpharmacology at the Johns Hopkins
University', Bull. Hist. Med., 1982, 56:512-27; idem,
J.J. Abel and the development ofAmerican
pharmacology: the shaping ofa discipline,
Baltimore, Johns Hopkins University Press, 1992,
especially pp. 57-8; and J W Fisher, 'Origins of
American pharmacology', Trends inpharm. Sci.,
1986, Feb., pp. 41-5.
29 See the references given in footnotes 63, 64 and
65 below, and 0 von Furth, 'The catechol-like
substance ofthe suprarenal', J. Chem. Soc. Abstracts,
1900, 78:292, from Z Physiol. Chem., 1900,
29:105-23. Some ofthese efforts are developed in H
W Davenport, 'Epinephrin(e)', Physiologist, 1982,
25:76-82, an article which details some of the
commercial difficulties in America that were
encountered with Adrenalin(e). W Sneader, Drug
discovery: the evolution ofmodern medicines,
Chichester, John Wiley & Sons, 1985, ch. 6, 'Drugs
affecting nervous transmission', especially pp. 96-9,
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spelt with a capital "A" and without a terminal "e", behaviour that brought a whiff of
scandal to the pharmaceutical industry which was to last for many decades in America.31
But, by 1901, the word adrenaline, with a lower case "a" and with or without the terminal
"e", began to achieve widespread recognition in Britain as representing the active
principle of the suprarenal gland.32 This was especially so amongst physiologists and,
significantly, when Takamine presented a communication to the Physiological Society in
that year, he spelled the word with a lower case "a" and made no reference to any
commercial associations.33 Takamine's work stimulated much commercial and academic
interest, including that of Wellcome, who wrote to Dowson of the WPRL, "[T]he supra-
renal matter is exceedingly important and we ought not to be behind anybody".34
Thus, by 1906, adrenalin was the word that Henry Dale intended to use in his paper, but
could he, as a member of staff of the Wellcome organization, a body with a fierce
reputation fordefending its own trade names, be allowed to use awordregistered as arival
trademark?35 Wellcome ruled that he could not, and turned down Dale's request. The veto
from Wellcome, and criticisms from the staff of the WCRL, first embarrassed, and then
irritated, Dowson, who, as Director of the WPRL, had initially given Dale permission to
use the term. He interpreted Wellcome's censorship as criticism ofhis own authority, and
explained in a lengthy submission to Wellcome that Dale had already published the
disputed word without interference from the Company.36 To substantiate his case, he sent
Wellcome a quote from a current paper in the Journal of Physiology, illustrating the
contemporary use ofthe word adrenaline,37 and continued in his defence of the practice:
31 Many years later Dale recalled his first meeting,
in 1909, with Abel, "[who] as he told me quite
frankly when we met, had been rather suspicious of
me; I was then working in the Wellcome
laboratories, and he explained that he did not
approve ofpharmacological research with any sort of
commercial connexion. Cushny, however, had
persuaded him that I was not so bad as all that", H H
Dale, 'Tribute from the British Pharmacological
Society and personal reminiscences', in Tributes to
John Jacob Abelfromforeign societies, Baltimore,
Johns Hopkins University, 1957, pp. 5-12, 21-2,
quote on p. 8. C Voegtlin, 'John Jacob Abel,
1857-1938', J. Pharmacol., 1939, 67:373-406, gives
a detailed account ofthe relationship and
connections between Abel and Takamine.
32 The subject index to the Journal ofPhysiology
contains entries for 13 papers or abstracts with the
word adrenalin(e) in the title, before Dale's full
paper, the subject ofthis article, which finally
appeared in 1906 in vol. 34. The British Medical
Journal, the Lancet, Chemist andDruggist and the
Pharmaceutical Journal all used "adrenalin" or
"adrenaline" in their indices.
33 J Takamine, 'The isolation of the active
principle of the suprarenal gland', J. Physiol., 1901,
27: xxix-xxx (communicated to the Society by 0 F F
Grinbaum). Whether any pressure had been put on
him to conform to British practice is not known. For
details ofTakamine's career see F 0 Taylor, 'Jokichi
Takamine', in Dumas Malone (ed.), Dictionary of
American biography, 20 vols, London, Humphrey
Milford, 1936, vol. 18, pp. 275-6.
34 Wellcome to Dowson, 19 Dec. 1901,
TWFL:LB31, Letter/Memoranda Book 1901-1906,
pp. 1-2. Dowson does not appear to have replied, or
to have developed appropriate research work at the
WPRL.
35 Burroughs, Wellcome & Co. had only recently
been involved in a highly-publicized court action to
defend "Tabloid", see Turner, op. cit., note 6 above,
pp. 14-15, and James, op. cit., note 6 above, pp.
292-3, and 'Legal intelligence, High Court of
Justice, Chancery Division: the "Tabloid" case,
Pharmaceut. J., 1903, 71:925-7.
36 Wellcome was abroad and Dowson's letter was
passed, according to standard practice, through the
Company headquarters. Thus started the
communication avalanche. The previous
communication referred to is H H Dale, 'The
physiological effect ofchrysotoxin', J. Physiol.,
1905, 32: lviii, and it must be inferred from the
correspondence that Dowson had permitted the
earlier use ofthe disputed word.
37 J N Langley, 'On the reaction ofcells and of
nerve endings to certain poisons, chiefly as regards
the reaction of striated muscle to nicotine and to
curare', J. Physiol.. 1905, 33: 374-413, especially p.
407.
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[Dale] proposes to adopt the term "Adrenaline" the added "e" making the term indicate a basic
substance conformably to the practice of chemists. The term thus spelled would take its place in
scientific nomenclature and be descriptive both of its origin and character. I trust this has your
consent; for although in papers published by the Chemical Society the substance is referred to as
"epinephrine" the use of a term based on the descriptive name "adrenal" appears to be unavoidable
in a physiological paper. The fact is that physiologists do not recognise the substance by any other
name.38
Wellcome was not impressed by Dowson's rejoinder, and continued to insist that the
physiologists should use the word epinephrine in line with the practice of staff from the
chemical labs. At this point scientists from the WCRL, principally Dr Hooper Jowett,
explicitly entered the debate, although it seems likely that they had been involved from
the very beginning.39
Hooper Jowett, Power's deputy at the Chemical Laboratories, was a distinguished
scientist with several published papers on epinephrine, and a recognized authority on its
chemistry.40 He and Power now tried to impose that authority on the physiologists, and
argued strongly that the word epinephrine was scientifically correct. The fact that
physiologists considered Abel's epinephrine physiologically inactive was irrelevant.
Jowett urged Dowson to comply with Wellcome's wishes:
Bearing in mind the very strong reason that Mr. Wellcome has for the avoidance of the name
'adrenalin', I think we ought to do everything possible to carry out his wishes in this matter. As
regards the Chemical Society, there is no difficulty about continuing to use the name 'epinephrine',
as we have there a precedent to follow, and it is clearly indicated in my first paper what is meant by
'epinephrine'. As regards other Societies and publications, I think that we could lay a very strong
case before them for the use ofthis name 'epinephrine'....
[I]t seems to me that with the position the firm occupy and the scientific standing of the two
Research Laboratories, it ought to be possible to convince any editor as to the reasonableness ofour
request to continue to use the name 'epinephrine' pointing out that we have done this since we
published any work on this subject [his emphasis].41
Dale was quite unable to accept this viewpoint as he perceived an essential difference
between the requirements ofthe physiologist and the chemist. He replied:
38 Dowson to Wellcome, 2 Feb. 1906. The request
did not receive Wellcome's assent: see Wellcome's
comments on Dowson's letter, 5 Feb. 1906; Pearson
to Dowson, 8 Feb. 1906. All in TWFL: Acc 82/1:
Box 23 'WPRL 1895-1922'. The authoritative
Britishpharmacopoeia then available was a 1905
reprinting ofthe fourth edition published in 1898 and
thus offered no guidance on the matter. By the time
the fifth edition appeared in 1914 adrenaline, but not
epinephrine, was listed, and no mention was made of
any trade name associations. Martindale's Extra
pharmacopoeia of 1906 referred to "Adrenalin" as
the active principle ofthe suprarenal gland, and
listed several similar preparations, whilst the British
pharmacopoeia codex of 1907 listed "adrenaline"
and mentioned that adrenalin was a trade name.
39 There is evidence ofprevious disagreements
between Jowett and Dowson over the Company's
suprarenal gland preparation (marketed as Hemisine)
and its physiological standardization, with batches
apparently being issued by the company without
WPRL authority, see Dowson to Pearson, 'The
physiological assay ofhemisine', 18 Sept. 1905,
WIHM:HSW 'WPRL Material'. The physical
proximity ofthe WCRL to the Company
headquarters may account for the lack of written
evidence oftheir earlier involvement.
40 For example, H A D Jowett, 'The constitution of
epinephrine', J. Chem. Soc., 1904, 85:192-7; G
Barger and H A D Jowett, 'The synthesis of
substances allied to epinephrine', ibid., 1905,
87:967-74. Unlike later work, in which Wellcome
chemists and physiologists collaborated onjoint
investigations, Jowett's papers never reported
physiological data.
41 Jowett to Dowson, 20 Feb. 1906, WIHM:HSW.
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In physiological literature the terminology is settled by those who describe the physiological action.
Schafer first described the action here in question and Langley first investigated it in detail. Neither
these nor other physiologists owed anything to Abel's work or could make use of his inactive
substances.42
Further, Dale reminded Wellcome, physiologists were not particularly concerned with
the chemical structure of the compound (a somewhat ironic comment from a man whose
career did much to establish the relationship between physiological action and chemical
structure), and he emphasized that the major, definitive physiological paper on the subject
published in the Journal ofPhysiology, by T R Elliott, had been entitled 'The action of
adrenalin'.43 If he, Dale, now attempted to use the word epinephrine he would, by
implication, be ignoring and discrediting the authority of physiologists whose work had
made his own possible. Dale concluded that ifthe word adrenaline could notbe employed,
then the paper could not be published in the Journal ofPhysiology, and his position at the
WPRL would be untenable. "[T]his I should most sincerely deplore, but the result would
be inevitable".44 To support his position Dale enclosed an authoritative statement by the
Editor ofthe Journal ofPhysiology, J N Langley,
adrenalin is now the scientific name, & has become so rooted that it is futile to try & make scientific
people go back on this & adopt instead a name which has been used & failed.45
This had immediate effect. Wellcome promptly acknowledged that these arguments
altered his viewpoint, and he accepted that the use of "adrenaline" in physiological
publications was unavoidable. Although Dale's hint at resignation indicated, "a lack of
mutual confidence and respect", he approved the paper, hoping, nevertheless, that Dale
would distinguish the active chemical from the product of a rival company.46
Thus the matter appeared to be settled. But the sanction was short-lived: less than
twenty-four hours laterWellcome cabled Dowson forbidding the paperto be submitted for
publication, and the next day a long letter arrived at the WPRL, explaining why he had
withdrawn his permission to use the word adrenaline.47 What changed his mind so
precipitately? It was a copy of a letter from Jowett, originally sent to Dowson, pushing
further the chemists' argument forepinephrine.48 Jowett alluded to the legal problems that
42 Dale to Wellcome, 20 Feb. 1906, WIHM:HSW.
The word adrenaline also achieved widespread
general usage in continental Europe, see S Fraenkel,
Die Arzneimittel-Synthese aufGrundlage der
Beziehungen zwischen chemischen Aujbau und
Wirkung, Julius Springer, Berlin, 1906, pp. 424-5.
The copy in the Wellcome Institute Library
originally belonged to the WPRL.
43 Dale and Elliott collaborated closely in their
complementary experimental work, and performed
joint experiments at the WPRL and in Cambridge.
Elliott's paper contains a specific acknowledgement
to Dowson and the WPRL for the provision of
facilities, see T R Elliott, 'The action ofadrenaline',
J. Physiol., 1905, 32:401-67, especially p. 411.
44 Dale to Wellcome, 22 Feb. 1906, WIHM:HSW.
45 The series of letters that resulted in this
statement are: Langley to Dale, 15 Feb. 1906; Dale
to Langley, 16 Feb. 1906; Dowson to Pearson, 16
Feb. 1906; Dowson to Pearson, 18 Feb. 1906. All
letters in WIHM:HSW. However, even two years
later, another eminent physiologist, Edward Schafer
suggested the word "adrenine" to obviate the
commercial associations of "adrenaline" and the
chemical confusions of"epinephrine", see E A
Schafer, 'Oliver-Sharpey lectures on the present
condition of our knowledge regarding the functions
ofthe suprarenal capsules', Br med. J., 1908,
i:1277-81, 1346-51, especially p. 1281.
46 Wellcome to Dowson, 25 Feb. 1906, Wellcome
to Dale, 25 Feb. 1906, both letters in WIHM:HSW.
Annotated carbon copies ofboth in TWFL:Acc 82/1:
Box 23 'WPRL 1895-1922'.
47 Telegram, Wellcome to Dowson, 27 Feb. 1906,
letter, Wellcome to Dowson, 27 Feb. 1906, both in
WIHM:HSW.
48 Jowett to Dowson, 20 Feb. 1906, sent by
Dowson to Wellcome, WIHM:HSW.
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might arise if Dale used the rival trade name and, with an eye to his own position at the
WCRL, suggested that it was time to correct the erroneous use of "adrenaline" in
physiological literature, and to ensure conformity in all publications coming from the
Wellcome laboratories. Wellcome's considerable respect for Jowett's reputation and
authority ensured that the latter's comments carried much weight, especially as they
reinforced concerns about the legal position. Wellcome's long reply to Dowson and Dale,
although acknowledging that the word was a "scientific descriptive term", raised, yet
again, the legal problems if they infringed another company's trade name. He called on
the physiologists to find "the moral courage" to correct their misuse of the word
adrenaline, emphasizing, with more than a hint of a crusade:
Surely we are not so lacking in our resources or in our spirit ofresearch that we cannot find some
solution fair andjust to all concerned. Why should we be faint-hearted? Our whole career has been
strewn with difficulties and our successes largely incited by them. We certainly have not exhausted
ourselves in this very limited discussion ... 49
He put forward the practical proposal that all the interested parties, including
representatives from the Physiological and Chemical Laboratories, and Company
headquarters, should get together, motivated by
[T]he earnest desire we all have to hasten the publication of the ergot work which means
professional interest to the WPRL and business interests to the firm.50
He further suggested consultation with Professor Langley from Cambridge, and DrAlfred
Chune Fletcher,51 whom he considered
one ofthe ablest medico-legal experts in the Kingdom. Hisjudgements I find as wise when they are
against me as when they are in my favour. In his wisdom I feel confident you will gain somehelp.52
Dowson and Dale responded immediately to this set-back, although from different
standpoints. By this stage, five weeks into the discussions, Dowson focused on his own
authority and position as the independent Director ofthe WPRL. He stressed that he had
received Wellcome's authorization with relief, especially as it would guarantee the future
"moral support" ofthe Cambridge Physiological School, and expressed his indignation at
what he now interpreted as unwarranted interference from members of the WCRL and
from Wellcome himself. He reminded Wellcome
If there is one subject more difficult to handle than another in scientific laboratories owned by the
principal of a commercial firm it is the publication of work; and the degree of restriction under
which this is done affords a sure test of the scientific status of such laboratories. To take care that
49 Wellcome to Dowson, 27 Feb. 1906, and Wellcome used fairly often to go offfor
WIHM:HSW. weekends together, but Fletcher was too discreet, and
50 Ibid. too loyal to talk about the extraordinary and
51 Chune Fletcher was a close friend and adviser of paradoxical mixture ofcharacteristics in Wellcome ...
Wellcome, frequently consulted on matters of [He was] my very good friend and adviser in my
medical "etiquette" and ethics, such as the problems early days of service and dispute with Wellcome", 6
ofachieving Home Office registration for the WPRL. June 1958, Royal Society Archives, Sir Henry Dale
Dale, in later life, commented to T R Elliott, "I papers, 93HD 36.4.29 'T R Elliott'. See also
suppose that Alfred Chune Fletcher, the Medical WIHM:HSW papers on Chune Fletcher.
Officer to the Charterhouse ... knew him 52 Wellcome to Dowson, 27 Feb. 1906,
[Wellcome] better than anybody else did. Fletcher WIHM:HSW.
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no restrictions arising purely out of commercial considerations should hamper the workers here is
at once the most delicate and responsible task of the director; and yet, under a misapprehension of
the ethics of the epinephrin position, you appear to be bent on exercising a power of veto which to
your director appears to be unjustifiable. The final adjudication on the question which has arisen is
the one thing which you should leave to me after assuring yourself that I have not overlooked any
important considerations.53
Dowson concluded his trenchant remarks with further objections to Jowett's continuing
involvement and grudging acceptance ofChune Fletcher as a "referee" in the debate.
Dale's response to Wellcome was equally uncompromising, and scathingly critical of
Jowett's opinions, "Dr. Jowett's convictions are interesting; they may even be true: but
they are entirely beside the point".54 But, exhibiting an early flair for the diplomatic and
political activities that were to become major responsibilities in his later life, Dale had
made an important connection that Dowson had not-he had been to talk to Chune
Fletcher.55 Dale was thus confident, when writing to Wellcome, of the nature of Chune
Fletcher's recommendations. He was careful to address only the problems of scientific
importance, and made no mention of the issues of authority and interference that so
agitated Dowson. Dale emphasized yet again that the chemical called epinephrine,
isolated by Abel and used by chemists, was not physiologically identical to the crude
gland extract, although he recognized, and sympathized with, the difficulties raised by the
episode. He added a powerful coda:
The position is one offar more difficulty than you, probably, can conceive. There is among English
medical men and particularly among physiologists, a strongly marked prejudice against any
connection with commerce. That prejudice I am earnestly and constantly trying to break down on
my own behalf, and on that of any pharmacological workers in your laboratories. I have great hope
of success: but the position I am striving for, on your behalf as well as my own, would be seriously
imperilled by a breath of suspicion that the publication of my work was hampered or modified by
other than scientific considerations.56
Those arguments were well targeted. Simultaneously Chune Fletcher, after interviewing
all the participants in the debate, reported to Mr Pearson, who relayed the opinion to
Wellcome:
Mr C.F. [Chune Fletcher] tells me that his opinion of the matter is that Dr. J. [Jowett] is right from
a chemical point of view & Dr. Da [Dale] is right from a physiological point of view, and as a
physiologist he cannot describe the substance with which he has been working as 'Epinephrine'-
the substance Dr Da has been working with is known to physiologists as 'adrenaline'[underlined in
red in the original].57
53 Dowson to Wellcome, 5 March 1906, heavily annotated by Wellcome, is in TWFL: Acc
WIHM:HSW. A copy ofthis, in TWFL: Acc 82/1: 82/1: Box 12.
Box 23 'WPRL 1895-1922', was received by Henry 57 Report ofChune Fletcher's opinion, by Pearson
Wellcome, and the lengthy passage quoted is to Wellcome, undated, but c. early March 1906,
underlined and annotated by him. TWFL: Acc 82/1: Box 23 'WPRL 1895-1922'.
54 Dale to Wellcome, 6 March 1906, TWFL: Acc These notes also make it apparent that Dale had
82/1: Box 12. independently consulted Chune Fletcher before the
55 See note 57 below. latter's formal involvement in the affair, and that his
56 There are two extant copies ofthis letter, Dale to controversial letter cited in note 44 above, in which
Wellcome, 6 March 1906: the carbon copy from the resignation had been obliquely indicated, had been
Company files is in WIHM:HSW; the original, written on Fletcher's advice.
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Faced with this barrage Wellcome finally agreed, on 8 March, that, subjecttothe inclusion
of an explanatory footnote differentiating the preparations used, Dale could submit his
paper.58 Having learned from the previous short-lived dispensation, Dale immediately
despatched his manuscript to the Journal ofPhysiology in Cambridge, diplomatically but
purposively, writing to Wellcome:
I hope that the vigour with which I have urged the difficulties in the way of changing the attitudes
of the physiological world has not given you the impression that I viewed at all lightly the
difficulties ofthe commercial position.59
Thus ended Dale's direct involvement in an incident that had been enormously
worrying: his wife was expecting their second child, and his employment prospects,
should resignation have been necessary, looked bleak. Despite Wellcome's decision,
Jowett continued his campaign for the sole use of epinephrine for some months, a
campaign to which the staffofthe WPRL remained completely unresponsive.60
The Significance ofthe Debates
These debates are instructive at several levels, including the legal, the scientific and the
personal. Whatever the precise legal situation that prevailed atthe time, the discussions about
the propriety of infringing another company's rights, and indeed the relevance of ethical
pharmaceutical advertising to the proper conduct ofmedical research were at the heart ofthe
dilemma facing Wellcome. There is only a hint in correspondence between Henry Weilcome
and the Managing Director of the Burroughs, Wellcome Company, that Parke, Davis & Co.
hadthreatenedlegalactionin 1906,andnoconfinnationofthishasbeenfoundinotherrecords
relating tothelabs orto theCompany.61 Neithercan Ifind stng evidence that adrenaline was
aregistered trade name forParke, Davis & Co., in Britain atthattime. Many years later, when
challenged about the incidentby an American pharmacologist, Henry Dale admitted:
Investigation showed, however, that they [Parke, Davis & Co.] had no trademark for the name in
this country, and they had in fact, never had one. I do not pretend to know the reason as to why they
58 Wellcome sent formal copies ofhis permission
("Dear Sir", rather than the usual "Dear Dr.
Dowson") to the WPRL and to Mr Pearson ofthe
Company. Several further items ofcorrespondence,
querying and then confirming the precise wording of
the footnote, all dated between 8 and 10 March 1906,
are in WIHM:HSW. The published footnote reads,
"In accordance with physiological custom the name
'adrenaline' is used throughout this paper to denote
the active principle ofthe supra-renal gland, in
whatever form administered. Simple extracts ofthe
gland, commercial preparations issued under various
'brand' names, and solutions ofthe pure base,
without preservative, were all used, and all give the
effects described", H H Dale, 'On some
physiological actions ofergot', J. Physiol., 1906,
34:163-206, quote on p. 169.
59 Dale to Wellcome, 14 March 1906, TWFL:Acc
82/1:Box 23 'WPRL 1895-1922'.
60 Differences between academic and commercial
concerns continued however: for example, the British
chemist H D Dakin, working in 1906, wrote, "A
considerable part ofmy work has, however, been
anticipated by workers in the laboratory ofMeister,
Lucius & Bruning ... I take the opportunity of
stating that my results were entirely independently
arrived at, and that owing to the method of
publication adopted (Patent Specifications), it is only
recently that I have become acquainted with the main
portion oftheir work", see H D Dakin, 'The
synthesis ofa substance allied to adrenalin', Proc. R.
Soc. Lond. B., 76: 491-7, quote on p. 491.
61 The hint is in confidential Company
correspondence, but no confirmation has been
located, Wellcome to B W & Co. [n.d. but between 3
and 7 March 1906] TWFL:LB32 Letter Book, April
1905 to March 1906, p.78. However Parke, Davis &
Co had proved litigious in other countries, see, e.g.,
Chemist andDruggist, 1904, 64:377, 934; 65:22,
495, 547.
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did not obtain registration. There is, however, one salutary item in the English law on the subject,
which may have had something to do with it. The English law recognises the trademark only as
indicating the preparation of a particular firm, and, if the owner of the trademark allows it to pass
into currency as the general name of the substance, apart from his particular manufacture, he loses
all rights in the trademark, and it is removed from the Register. I do not think that the American law
is as strong on this point. In any case it has suited Parke Davis's purpose, I think, to allow the name
'adrenaline' to be freely used in English scientific literature, and at the same time keep tight hold of
their trademark rights in the United States.62
So were Henry Wellcome and his advisers being extra cautious in trying to head off a
threat before it appeared, or was even known to exist? Or did the Wellcome chemists use
the possibility of a legal problem as a cover, or a threat, to try to force the physiologists
into line with their normal practice?
That leads to a second feature ofthe debates-the professional relationship between the
chemists and the physiologists employed by Wellcome. At first glance the whole
disagreement might be interpreted as a fundamental scientific difference-on the one
hand, a compound that the chemists had abstracted from the adrenal glands and named
epinephrine, and, on the other hand, an argument from physiologists that epinephrine was
not physiologically identical to gland extracts in their tests and that another word was
necessary forthe active material. FromTakamine's chemical workthis active material was
known to be the substance called adrenalin. There thus seems to be little scientific reason
for the chemists to have become heavily involved in the discussions, as the immediate
problem was not one of scientific terminology but of the possible infringement, and
subsequent liabilities, of Parke, Davis' rights. By suggesting that a solution, indeed the
solution, to the problem was the imposition of an unsuitable word, the chemists added
confusion and fostered resentment.
The history ofthe word "epinephrine", as originally proposed by Abel and Crawford in
1897, is chequered. The following year, Abel acknowledged that his extraction method
was not yet perfected, "[TIn its native state, as found in the suprarenal capsule, this
substance differs by one chemical reaction only fromits state as described in thispaper."63
Abel's further chemical work continued to refine his extraction procedures. The
difficulties imposed by the continuing use ofthe word epinephrine for his extracts during
this on-going process, led him to concede:
At the present moment it is impossible to express in analytical terms, the differences that exist
between the epinephrine of my former papers and the somewhat less altered nativeprinciple.64
62 Dale to Leake, 15 Oct. 1935, RS 93 HD. 173-4, lists a further 57 synonyms, including
39.25.4. Dale may well have been correct in "takamina".
believing that Parke, Davis gained from allowing 63 J J Abel, 'Further observations on the chemical
free use of the word in England. The details ofthis nature ofthe active principal ofthe suprarenal
debate emphasize that historically "epinephrine" and capsule', Johns Hopkins Hosp. Bull., 1898,
"adrenaline" are not the same substance, although 9:215-18, quote on p.218. Abel's own research
they are now considered to be so. E E J Marler depended on the generosity ofMessrs P D Armour &
(compiler), Pharmacological and chemical Co. ofChicago and the assistance ofG A Manns, the
synonyms: a collection ofnames ofdrugs and other company's chiefchemist.
compounds drawnfrom the medical literature ofthe 64 JJ Abel, 'Furtherobservations onepinephrin', Johns
world, Amsterdam, Excerpta Medica, 1973, pp. HopkinsHosp. Bull., 1901, 12:80-4, quote on p. 84.
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Andjust a few months later he presented a detailed comparison ofa series ofepinephrine
compounds with Takamine's adrenalin, and von Furth's "suprarenin". Hampered by
Takamine's failure to describe his methods or to provide adequate analytical data, Abel
suggested that adrenalin, which he admitted was more physiologically active than
epinephrine, was in fact a mixture and not an individual substance.65
These detailed arguments continued for some time and are beyond the scope of the
present paper. They do, however, show the importance of the point made by Henry Dale
in his campaign, that there were significant and relevant physiological differences
between the variously named chemicals.66 From the correspondence and other papers
examined in this case-study, it appears however that these empirical scientific arguments
about chemical and physiological nomenclature were not seriously considered within the
company, despite the efforts of some ofthe proponents, especially Dale and Jowett.
What is clear, is that personal differences between Jowett and Dowson coloured their
responses. Confidential notes made at the time by Wellcome on some ofthe personalities
are immensely revealing. His opinion ofDale reads,
Dr Dale is a very able man and has will and a way ofhis own that needs very diplomatic handling
& he has very strong ideas about professional ethics and, I think he probably knows & has thought
more about this side which it is necessary for us to keep in view-I am sure Dr Dale will not
intentionally do anything not strictly loyal ... I consider him the best man in his work I have ever
met-for a young man, and he is developing well & I want him to develop my ideals in this
Physiological work-in which we are far ahead ofothers.67
His view of Dowson was far less flattering, and underlines how the conflict of
personalities influenced the nomenclature debate,
I am afraid that Dr D[owson] is and has been throughout this discussion in one ofhis 'moods'....
I fear that he personally farmore than Da[le] is responsibleforiie present situation ... DrD[owson]
lacks tactfulness and as we know by past experience when he is in his 'moods', stirs up & fosters
discord and suggests bad motives and uses regretable expressions-I am deeply sorry that he has
got his knife into Jow[ett].... I am afraid from the tone of the correspondence that Dr. D[owson]
65 For example, J J Abel, 'On the behaviour of
epinephrine to Fehling's solution and other
characteristics ofthis substance', Johns Hopkins
Hosp. Bull., 1901, 12:337-43, especially,
'Comparison ofepinephrin with the substances
known as suprerennin [sic] and adrenalin', pp. 34-2;
idem, 'On a simple method ofpreparing epinephrin
and its compounds', ibid., 1902, 13:29-36; idem,
'On epinephrin and its compounds, with especial
reference to epinephrin hydrate', Am. J. Pharm.,
1903, 75:301-25. The later discovery, that the
medulla ofthe adrenal gland contains both
adrenaline and non-adrenaline, the latter being more
physiologically active, provides an additional
explanation for the chemical and physiological
confusion, see, e.g., Ulf S von Euler, Noradrenaline:
chemistry, physiology, pharmacology and clinical
aspects, Springfield, Ill., Charles C Thomas, 1956,
especially pp. 109-16. Abel, in later life, commented
that epinephrine was "the name coined by me thirty
years ago at a time when I supposed that the form in
which I had succeeded in isolating it represented the
base as it actually exists in the capsules", and
acknowledged that the confusion and competing
claims at the time meant that "I can not look back on
my own poor efforts to elucidate the chemical
constitution ofthe compound with pleasure", in J J
Abel, Chemistry in relation to biology and medicine
with especial reference to insulin and other
hormones, The Willard Gibbs Lecture, Baltimore,
Williams & Wilkins, 1939, especially pp. 60-7.
66 This was also emphasized by Parke, Davis &
Co., see for example their letter, 'The pharmacology
of the suprarenal gland', Pharmaceut. J., 1903,
71:870.
67 Consecutive undated notes, Wellcome to BW &
Co, c. Feb. 1906, TWFL:LB32 Letter Book,
Feb.-April 1906, p.25, emphasis as in the original.
Wellcome's recognition ofhis ability led him to
appoint Dale as Director ofthe WPRL later in 1906
when Dowson resigned for reasons unconnected with
the present incident.
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made up his mind early and then as he too frequently does closed his doors to conviction and
regarded anyone who differed from him as wrong. This with Dr. D[owson] is a matter of
temperament for temperament governs his moods & methods.68
Thus Dowson's temperament, and the threat of legal action, real, imagined, or
deliberately manufactured, contributed greatly to the escalation and maintenance of the
dispute. Equally important was the question of scientific authority, both within the
Wellcome organization and, more critically, in wider medical and scientific circles. Some
ofthe tensions between the Physiological and Chemical labs were engendered by the fact
that the staff of the WCRL wished to control those they clearly regarded as theirjunior
colleagues. But, more significantly, this controversy and its resolution illustrated the
personal aspirations of Henry Wellcome to achieve scientific respectability, and
acceptability, for his laboratories. From its establishment, Burroughs, Wellcome & Co.
used scientific language and symbolism to advertise their products, and to promote
themselves as advanced, responsible pharmacists. The creation ofapparently independent
laboratories, run on high-minded scientific principles untainted by commercial
considerations, further enhanced and extended that representation. That image was
projected very successfully to pharmacists, general medical practitioners and other
pharmaceutical manufacturers. However, as Wellcome discovered when he tried to
register the WPRL for animal experimentation, that claim had not impressed either the
senior medical establishment or government officials, who viewed the Company and its
laboratories not as scientists, but as mere commercial tradesmen who could not be
accorded the rights and privileges given to men of medical and scientific standing.69
Wellcome's eventual success at getting his laboratories registered under the 1876 Cruelty
to Animals Act was a considerable achievement. Thus, challenged about the scientific
independence ofthe labs, when the question ofusing the word adrenaline arose, Wellcome
was torn between commercial propriety and scientific credibility. He showed himself
particularly sensitive to the advice of J N Langley, and heeded the caution of Dale and
Chune Fletcher that an imprudent decision imposed on the physiological laboratories
would do irreparable harm to his schemes and ambitions. Ultimately, the claims for
scientific reputation and independence won.70
In a letter to Wellcome during the dispute, Dale had spelled out very clearly the
difficulties of pursuing scientific research in an establishment associated with a
commercial firm. He promised Wellcome that he would discuss, with Frederick Gowland
Hopkins, the Chairman ofaPhysiological Society committee onproteidnomenclature, the
possibility of extending that committee's terms of reference to include the problems of
using commercial preparations.71 His final paragraph summarizes the novel problems that
68 Ibid. earlier campaigns for Home Office registration, see
69 The debates on the animal experimentation issue Tansey, op. cit., note 5 above, pp. 28-9.
and their resolutions are documented in Tansey, op. 71 Dale to Wellcome, 14 March 1906, TWFL:Acc
cit., note 5 above. 82/1:Box 23 'WPRL 1895-1922'. An annotated
70 The adrenaline/Adrenalin debate was much copy [by Wellcome?] is in WIHM:HSW. Dale
easier for Wellcome to be accommodating on, than admitted, "I confess, however, that I have no great
say, allowing publication of a paper that reflected hope in the matter", and I have been unable to find
negatively on a company product. The WPRL's evidence that the Proteid Nomenclature Committee
stance on openly publishing commercially profitable did consider commercial preparations.
and patentable procedures was questioned during the
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faced the Physiological Research laboratories, encapsulated, and in this instance resolved,
in the dispute about the use ofthe word adrenaline.
The question is at bottom a practical one. The connection between chemistry and commerce is an
old and honourable one: that of physiology is a new thing to England, and regarded withjealousy
and suspicion by the 'professionally correct' medical and physiological people. You may not know
that my predecessor Dr Shaw was blackballed by the Physiological Society merely on the grounds
of his supposed connection with commercial interests. The situation needs delicate handling, and I
am sure I may rely on you for any possible concession to old-fashioned prejudice, provided that it
is compatible with dignified independence and due regard to your firm's interests. You will see how
difficult it is for me to press a matter of this kind when there are people always ready to detect a
commercial manoeuvre in the policy of these laboratories. But I am going to do what I can: and I
hope some day to see the aid ofcommerce by physiology recognised as an important and desirable
branch of medical science in England, and to see your laboratories recognised as the pioneer
institution.72
Recalling the incident in his Personal Record at the Royal Society, Henry Dale
commented over fifty years later,
I am not nearly so sure now, as I was then, that I was completelyjustified to the merits ofthe case.
I am very sure however, that I won an important victory for the staff ofthe Laboratories.73
At a personal level, the adrenaline episode was of considerable significance in Dale's
maturation as a scientist and scientific tactician, representing the first ofmany episodes in
his career associated with the correct use of pharmacological terminology. His personal
research work attracted attention from pharmacologists at home and abroad, as
exemplified by a particularly pertinent comment from the British pharmacologist, A R
Cushny, writing to J J Abel in 1909.
There is a very good man H. H. Dale here, who has done well with ergotoxin and is I think one ofthe
mostpromising men about. Thedifficulty isthatheispharmacologisttoBurroughs andWelcome [sic],
and though that does not affect his work, you might not wish to make a precedent. He is not at all
concerned in pushing the products ofthe firm however, and simply works in his laboratory.74
72 Dale to Wellcome, ibid. A careful examination
ofthe Candidates Books ofthe Physiological Society
has failed to reveal confirmation ofDale's assertions
about Vernon Shaw. Shaw was elected to the Society
in 1904, without apparent opposition or undue delay,
Physiological Society Archives, Contemporary
Medical Archives Centre (CMAC), SAIPHY/E.2/3,
see also, 'W.V. Shaw, OBE', Nature, 1937, 1:359.
The attitude ofthe American Society for
Pharmacology and Experimental Therapeutics was
much harsher: they forbade membership to anyone
associated with a pharmaceutical company, see J
Parascandola, 'The "Preposterous Provision": The
American Society for Pharmacology and
Experimental Therapeutics' ban on industrial
pharmacologists, 1908-1941', in J Liebenau, G J
Higby, and E Stroud (eds), op. cit., note 12 above,
pp. 29-47.
73 Feldberg, op. cit., note 2 above, quote on p. 98.
74 Cushny to Abel, 22 Feb. 1909, A R Cushny
papers CMAC/PP/ARC/D.1. Abel had requested
advice on inviting a British pharmacologist tojoin
the editorial board ofthe Journal ofPharmacology.
Cushny's reply indicates yet again some ofthe
prejudices extant about the association of scientists
with pharmaceutical companies. For further details of
Abel's attitude towards pharmaceutical companies
see Parascandola, J. J. Abel, op. cit., note 29 above,
especially, 'The bias against industrial
pharmacologists', pp. 115-25; idem, op. cit., note 28
above. See also note 31 above. For a wider American
perspective see J P Swann, Academic scientists and
thepharmaceutical industry: cooperative research in
twentieth-century America, Baltimore, Johns
Hopkins University Press, 1988, especially ch.2,
'The rise ofuniversity-industry interactions in
biomedical research'.
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In 1913, still employed by Wellcome, he was appointed an official adviser to the British
pharmacopoeia; during the First World Warhe provided advice and technical expertise to
British manufacturers attempting to replace suspended German patents; after that war the
creation and proper identification of national and international biological standards were
majorofficial concerns ofDale; and inhis research workhis ability to distinguish, classify
and name drug effects made enormous contributions to the development of work on the
chemistry ofthe nervous system.75
The resolution of the adrenaline debate was pivotal in emphasizing the independent
scientific autonomy ofthe WPRL and its staff, as Wellcome had sofrequently proclaimed,
somewhat inaccurately, in the past. It also established a base for scientific excellence that
distinguished research associated with the Wellcome organization for many decades.76
The fostering of scientific research in the environment of a pharmaceutical company had
created novel problems. Nevertheless, by addressing such unforeseen difficulties, the
Wellcome company managed to develop policies to accommodate pure scientific work
alongside commercial interests, policies that were later emulated by other companies.77
75 For further details of Dale's career, see
Feldberg, op. cit., note 2 above, and Tansey, op. cit.,
note 2 above. His important contributions to
pharmacological terminology include
"sympathomimetic", "adrenergic", and "cholinergic",
see, e.g., H H Dale, 'Nomenclature offibres in the
autonomic system and their effects', J. Physiol.,
1934, 80: lOP.
76 In 1914 Dale became the first elected Fellow of
the Royal Society associated with a pharmaceutical
company, and several of his colleagues achieved the
same distinction, see Tansey, op. cit., note 5 above,
pp. 36-7. In 1936, then an employee ofthe Medical
Research Council, Dale was awarded a Nobel Prize,
the first offive scientists associated with the
Wellcome Laboratories to be thus honoured so far.
77 Such debates and dissensions continue to the
present day however, see the contemporary debate
about the word "Taxol", and the activities ofBristol-
Myers Squibb, e.g., Nature, 1995, 373:370.
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